(:AIMT)
Business Focus: N/A
Feb 25, 2021 09:00 am ET
Aimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA® for up to ~3.5 Years
Aimmune Therapeutics, a Nestlé Health Science company developing and commercializing treatments for potentially life-threatening food allergies, today announced new clinical data from a pooled analysis of three controlled phase 3 (PALISADE1, RAMSES, ARTEMIS2) and three open-label extension (ARC0043, ARC008, ARC011) trials of PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp]. These data will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting held February 26 – March 1, 2021.
Nov 19, 2020 08:00 am ET
Aimmune Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Aimmune Therapeutics, Inc. (NASDAQ: AIMT) investors that acquired shares relating to the sale of the Company to Sociétés des Produits Nestlé, S.A....
Oct 15, 2020 07:28 pm ET
Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of California
NEW YORK, Oct. 15, 2020 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Northern District of California, Case No. 4:20-cv-06733-YGR, on behalf of common shareholders of Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") (AIMT) who held Aimmune securities as of the close of the tender offer on October 9, 2020 (the "Class Period"), and have been harmed by Aimmune and its board of directors' (the "Board") alleged violations of Sections 14(e) and 20(a) of the Securities Exchange Act of 19
Sep 23, 2020 03:00 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of AIMT, BMCH, BYFC, and CGIX Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Aimmune Therapeutics, Inc. (NASDAQ GS: AIMT) regarding possible breaches of fiduciary duties and other violations of law related to Aimmune’s agreement to be acquired by Sociétés des...
Sep 23, 2020 07:00 am ET
Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies
Longitude Capital, a leading healthcare venture capital firm, today announced the closing of Longitude Venture Partners IV, L.P. (“LVP4”), with $585 million in capital commitments. LVP4, the largest fund that Longitude Capital has raised to date,...
Sep 16, 2020 01:24 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc., (NASDAQ:AIMT), Akcea Therapeutics, Inc., (NASDAQ:AKCA), BMC Stock Holdings, Inc., (NASDAQ:BMCH), and Cancer Genetics, Inc
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AIMT to Sociétés des Produits Nestlé, S.A. for $34.50 per share. If you...
Sep 04, 2020 07:37 pm ET
AIMMUNE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aimmune Therapeutics Inc. - AIMT
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Aimmune Therapeutics Inc. (NasdaqGS: AIMT) to Sociétés des Produits Nestlé, S.A. Under the terms of the proposed transaction, shareholders of Aimmune will receive only $34.50 in cash for each share of Aimmune that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Sep 03, 2020 12:52 pm ET
Moore Kuehn Encourages MNTA, AIMT, ONDK, and OTEL Investors to Contact Law Firm
Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek...
Aug 31, 2020 12:37 pm ET
AIMMUNE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AIMT and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Aimmune Therapeutics Inc. (NASDAQ: AIMT) breached their fiduciary duties or violated the federal...
Aug 31, 2020 12:01 pm ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Aimmune Therapeutics, Inc.
Rowley Law PLLC is investigating potential securities law violations by Aimmune Therapeutics, Inc. (NASDAQ: AIMT) and its board of directors concerning the proposed acquisition of the company by Nestlé S.A. Stockholders will receive $34.50 in cash for each share of Aimmune Therapeutics stock that they hold. The transaction is valued at approximately $2.6 billion and is expected to close in the fourth quarter of 2020.
Aug 31, 2020 01:15 am ET
Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science
Aimmune Therapeutics Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it has entered into a definitive agreement for Sociétés des Produits Nestlé, S.A. to acquire Aimmune for $34.50 per share in an all-cash transaction, implying a fully-diluted equity value of $2.6 billion. Sociétés des Produits Nestlé, S.A. is a part of Nestlé Health Science (NHSc) and a wholly owned subsidiary of Nestlé S.A. The agreement was unanimously approved by all of the independent members of the Board of Di
Aug 24, 2020 08:30 am ET
Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on Allergic Individuals and Their Caregivers
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that findings from APPEAL-2 (Allergy to Peanuts ImPacting Emotions And Life-2), the largest cross-sectional, pan-European, qualitative study to evaluate the psychosocial burden of living with peanut allergy, were published in Clinical & Experimental Allergy, the official journal of the British Society for Allergy & Clinical Immunology. The study highlights the substantia
Aug 07, 2020 08:00 am ET
Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 10:55 a.m. E.T.
Jul 30, 2020 04:05 pm ET
Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2020.
Jul 23, 2020 08:30 am ET
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Thursday, July 30, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter and six months ended June 30, 2020, and recent operational highlights.
Jul 21, 2020 08:30 am ET
Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA® Published in The Lancet Child & Adolescent Health
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that complete results from its pivotal phase 3 European ARTEMIS trial (AR101 Trial in Europe Measuring Oral Immunotherapy Success) of PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] have been published in The Lancet Child & Adolescent Health. ARTEMIS met all primary, secondary and safety endpoints, and demonstrated that participants treated
Jul 06, 2020 08:30 am ET
Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced the appointment of Narinder Singh as Executive Vice President, Technical Operations. Mr. Singh is a proven biopharmaceutical executive with over two decades of deep technical, operational, and strategic leadership experience in end-to-end biopharmaceutical clinical development and commercialization, launch, and life cycle management for a variety of biopharmaceuticals such as biologics, biosimilars, complex generics, p
Jun 08, 2020 08:00 am ET
New Data Show Patients Are Highly Satisfied With and Confident in the Efficacy of Daily Treatment With PALFORZIA™ After Nine Months
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced new findings from the phase 3 ARTEMIS trial that show patients with peanut allergy aged 4 through 17 were highly satisfied after nine months of daily treatment with PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first therapy approved by the U.S. Food and Drug Administration (FDA) for peanut allergy. Specifically, the report revealed that patients were confident that the treatment was effective
Jun 08, 2020 08:00 am ET
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced new two-year data that suggest long-term efficacy of daily treatment with PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in patients with peanut allergy. Patients dosed daily in the study also showed ongoing immunomodulation and higher rates of desensitization that increased over time compared to those patients who were administered non-daily dosing. Furthermore, the majority of patients in the dail
Jun 04, 2020 08:00 am ET
Aimmune Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 11:20 a.m. E.T.
Jun 01, 2020 08:00 am ET
New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented at EAACI 2020 Congress
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies, today announced it will present important new long-term safety, efficacy and immunological data from ARC004, an open-label, rollover study of the landmark pivotal PALISADE trial of PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp] and data on patient-reported treatment satisfaction from the European phase 3 ARTEMIS trial of PALFORZIA. In addition, insights from the PAPRIQUA study about the psychosocial burden of peanut allergy on
May 28, 2020 07:30 am ET
Largest European Quantitative Study on Peanut Allergy Confirms Significant Need, Burden and Psychosocial Impact of Peanut Allergy on Allergic Individuals and their Caregivers
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies, today announced that findings from APPEAL-1 (Allergy to Peanuts ImPacting Emotions And Life-1), a multi-dimensional pan-European study assessing the psychosocial effect and impact of living with peanut allergy, were published in Allergy, one of the official journals of European Academy of Allergy and Clinical Immunology (EAACI). The study, published in two parts (Part A and Part B), highlights the
May 12, 2020 08:00 am ET
Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will participate in a fireside chat at the RBC Capital Markets 2020 Global Healthcare Conference on Tuesday, May 19, 2020 at 4:50 p.m. E.T.
May 11, 2020 04:05 pm ET
Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced financial results for the quarter ended March 31, 2020.
Apr 30, 2020 08:00 am ET
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Monday, May 11, 2020, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2020, and recent operational highlights.
Apr 08, 2020 08:00 am ET
Aimmune Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will present at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020 at 2:50 p.m. E.T.
Mar 16, 2020 08:00 am ET
Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the first patients in the United States are being treated with PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first approved treatment for peanut allergy. Following the release of the medication lots by the U.S. Food and Drug Administration (FDA), specialty pharmacies are shipping PALFORZIA initial dosing kits to allergists for in-office administration to their peanut-allergic patients age
Mar 13, 2020 05:00 pm ET
Aimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability and Continued Immunomodulation After 18 and 24 Months of Treatment
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies, today announced new data from the clinical development program for PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first peanut allergy treatment approved by the U.S. Food and Drug Administration (FDA).
Feb 27, 2020 04:05 pm ET
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced financial results for the fourth quarter and full year 2019.
Feb 26, 2020 08:00 am ET
Aimmune Therapeutics to Present at Upcoming Investor Conferences
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will present at two upcoming investor conferences in March:
Feb 25, 2020 08:00 am ET
Aimmune to Present New Clinical Data at AAAAI Annual Meeting
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced it will present new data from the clinical trial program for PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first-ever peanut allergy treatment approved by the U.S. Food and Drug Administration (FDA). Additionally, the Company will present data on other topics, such as important insights into oral immunotherapy (OIT) practice patterns in a real-world setting. These data will be presented at the
Feb 20, 2020 08:30 am ET
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Thursday, February 27, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2019, and recent operational highlights.
Feb 05, 2020 08:06 am ET
Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that Nestlé Health Science will make an additional equity investment in Aimmune of $200 million, bringing Nestlé’s total investment in Aimmune to date to $473 million.
Feb 05, 2020 08:01 am ET
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it has obtained an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody XmAb®7195 from Xencor, Inc.
Jan 31, 2020 05:04 pm ET
FDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the U.S. Food and Drug Administration (FDA) approved PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp]. PALFORZIA is the first approved treatment for patients with peanut allergy. It is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. PALFORZIA is approved for use in patients with a confirmed diagnos
Jan 06, 2020 08:30 am ET
Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:30 p.m. P.T. in San Francisco.
Nov 15, 2019 04:05 pm ET
Aimmune to Participate in Three Upcoming Investor Conferences
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in three upcoming investor conferences in November and December:
Nov 08, 2019 11:00 am ET
New Data Presented at ACAAI 2019 Show Importance of Clinical History in Identifying AR101-Eligibile Patients for PALISADE Study without a Food Challenge
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today presented new data showing that a strong clinical history, in combination with evidence of peanut sensitization, is the optimal approach to identify peanut-allergic patients who are highly sensitive to peanut protein. These data were presented at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting in Houston.
Nov 08, 2019 11:00 am ET
Quality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New Treatments
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today presented results from two new surveys that examined the effects of peanut allergy on health-related quality of life (HRQoL) among adults and caregivers in the United States. The findings reinforce the need for new treatments in peanut allergy that may reduce concerns related to peanuts, decrease the potential risk of allergic reactions and improve the HRQoL of those impacted by peanut allergy: adult patients, children and their caregivers. These su
Nov 08, 2019 07:00 am ET
AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the results from a new analysis showing consistent efficacy and safety with AR101 across the phase 3 PALISADE and ARTEMIS trials, despite differing regions of study, entry criteria, therapeutic dosing periods and primary efficacy endpoints. The data were presented at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting in Houston.
Nov 08, 2019 07:00 am ET
New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today revealed that the logistical needs for implementing oral immunotherapy (OIT) for food allergies, such as peanut allergy, into clinical practice is comparable to those for subcutaneous immunotherapy (SCIT) for environmental allergies. These data were presented at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting in Houston.
Nov 06, 2019 04:05 pm ET
Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced financial results for the quarter and nine months ended September 30, 2019 and provided operational highlights.
Nov 04, 2019 04:05 pm ET
Aimmune to Participate in the Credit Suisse 28th Annual Healthcare Conference
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in a fireside chat at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 1:15 p.m. MST in Scottsdale, Arizona.
Oct 31, 2019 07:00 am ET
Aimmune to Present New Data on Safety and Efficacy of AR101, Clinical Practice Implementation of Oral Immunotherapy, Quality of Life and Other Related Studies at ACAAI 2019
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it will present new data on the safety and efficacy of the company’s lead investigational candidate, AR101 (trade name Palforzia™), at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting, taking place November 7-11, 2019, in Houston. Additional highlights include data from a half dozen studies, including real-world insights regarding the implementation of oral immunotherapy into clinical practice. AR101
Oct 30, 2019 07:00 am ET
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Wednesday, November 6, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2019, and recent operational highlights.
Sep 26, 2019 07:00 am ET
Aimmune to Present at the Cantor Global Healthcare Conference
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 8:20 a.m. E.T. in New York City.
Sep 13, 2019 05:53 pm ET
FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune’s PALFORZIA™ (AR101) for Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Allergenic Products Advisory Committee (APAC) convened by the U.S. Food and Drug Administration (FDA) voted to support the use of AR101 (proposed trade name PALFORZIA™) in children and teens with peanut allergy. PALFORZIA is a complex, biologic oral immunotherapy (OIT) candidate designed to reduce the incidence and severity of allergic reactions, including anaphylaxis, after accidental exposure to peanut in patients aged 4 through
Sep 13, 2019 07:05 am ET
Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA™ (AR101) for Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug Administration (FDA) Allergenic Products Advisory Committee (APAC) is holding a meeting today from 8:30 a.m. to 4:30 p.m. ET to discuss whether efficacy and safety data support licensure of PALFORZIA™ as a treatment to reduce the incidence and severity of allergic reactions, including anaphylaxis, after accidental exposure to p
Sep 12, 2019 09:00 am ET
Biotech Brief: Latest Electrophysiology Devices Vastly Improving Diagnosis and Treatment of Cardiovascular Diseases
According to a recent market research report published by Grand View Research, a consulting and advisory service firm that provides comprehensive, research-based views crucial for building business intelligence and overcoming market challenges,...
Aug 28, 2019 07:00 am ET
Aimmune to Participate in Three Investor Conferences in September
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in three upcoming investor conferences in September:
Aug 21, 2019 07:00 am ET
Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for Egg Allergy
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has randomized its first patient in a phase 2 clinical trial of AR201 for the treatment of egg allergy. AR201, an investigational biological drug for use in oral immunotherapy for egg allergy, is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform.
Aug 08, 2019 04:05 pm ET
Aimmune Therapeutics Announces Second Quarter 2019 Financial Results and Provides Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2019. Operational highlights for the second quarter of 2019 include:
Aug 06, 2019 07:00 am ET
Aimmune to Present at the Wedbush PacGrow Healthcare Conference
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019, at 3:05 p.m. E.T. in New York City.
Aug 01, 2019 07:00 am ET
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Recent Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Thursday, August 8, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2019, and recent operational highlights.
Jul 11, 2019 08:01 am ET
Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final Report on AR101 for Peanut Allergy
Aimmune Therapeutics (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, cautions stakeholders against drawing conclusions from the Institute for Clinical and Economic Review’s (ICER’s) final report on emerging desensitization treatments for peanut allergy, released yesterday. In its review, ICER fails to incorporate available data on both long-term outcomes and quality-of-life. ICER’s analysis and the public meeting discussion discounted patient and community perspectives on the physical, social and psychological benefits of desensitization.
Jun 28, 2019 07:00 am ET
Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for AR101, an investigational biologic oral immunotherapy to reduce the frequency and severity of allergic reactions following exposure to peanuts in children and adolescents ages 4 to 17.
Jun 12, 2019 08:00 am ET
Aimmune to Present at the JMP Securities Life Sciences Conference
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that its President and Chief Executive Officer, Jayson Dallas,
M.D., will present at the JMP Securities Life Sciences Conference on
Wednesday, June 19, 2019 at 2:30 p.m. E.T. in New York City.
Jun 11, 2019 08:00 am ET
Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, will present
at the Institute for Clinical and Economic Review’s (ICER) Public
Meeting reviewing the effectiveness and value of treatments for peanut
allergy, to be held today in Oakland, California. Aimmune is developing
AR101, an investigational biologic drug for use in oral immunotherapy as
a treatment to reduce the frequency and severity of allergic reactions
following exposure to peanuts.
Jun 05, 2019 08:00 am ET
Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that members of its Executive Management Team will participate
in a fireside chat at the Goldman Sachs 40th Annual
Healthcare Conference on Wednesday, June 12, 2019 at 9:20 a.m. P.D.T. in
Rancho Palos Verdes, California.
Jun 04, 2019 10:01 am ET
Data from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced new data from two studies that assessed the psychosocial
burden of living with peanut allergy. Results from APPEAL 2, the first
European multi-country qualitative evaluation of the impact of living
with peanut allergy, found that living in fear of a potentially fatal
reaction to peanuts significantly impacts the quality of life of
individuals with peanut allergy and their families. In addition, data
Jun 04, 2019 07:01 am ET
New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced results from ARC004, an open-label, rollover study of the
landmark Phase 3 PALISADE trial, which showed that extending daily
therapy with AR101 by an additional 28 weeks led to improved
tolerability with lower numbers of adverse events compared to the
PALISADE therapeutic dosing period, an increase in the amount of peanut
that could be safely ingested, and continued immunomodulation to peanut
pr
Jun 02, 2019 07:01 am ET
Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
presented topline results from the pivotal European Phase 3 ARTEMIS
clinical trial, which it previously announced had met its primary
endpoint, demonstrating the efficacy and safety of AR101 in
peanut-allergic children and adolescents after six months of dose
escalation and a three-month therapeutic dosing phase. The findings from
the ARTEMIS trial reinforce the consistent clinical profile of AR101,
demon
May 24, 2019 08:00 am ET
Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that it will present AR101 and patient quality of life data at
the European Academy of Allergy and Clinical Immunology (EAACI) 2019
Congress, taking place June 1 to 5, 2019, in Lisbon, Portugal. Of the
six abstracts accepted by EAACI, three are oral presentations and one is
a late-breaker poster presentation.
May 21, 2019 04:01 pm ET
New Study Shows More Than Half of Teens with Peanut Allergy Visited the E.R., More Than One-Third Required Hospitalization Due to Accidental Exposure to Peanut
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced results of a new study of U.S. adolescents with peanut allergy
that found more than half required a visit to the emergency room or
urgent care and one-third required hospitalization as a result of peanut
exposure in the past 12 months, despite the fact that 100% of those
surveyed reported actively avoiding peanut products. The study findings
were presented here today in a poster session at the Internat
May 16, 2019 08:30 am ET
Aimmune to Present at RBC Capital Markets Global Healthcare Conference
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that its Chief Financial Officer, Eric Bjerkholt, will present
at the RBC Capital Markets Global Healthcare Conference on Tuesday, May
21, 2019, at 2:35 p.m. E.T. in New York City.
May 16, 2019 08:00 am ET
Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that it has been informed by the U.S. Food and Drug
Administration (FDA) that the Allergenic Products Advisory Committee
(APAC) will review the Biologics License Application (BLA) for AR101 at
its meeting scheduled for September 13, 2019. Aimmune is developing
AR101, an investigational biologic drug for use in oral immunotherapy,
as a treatment to reduce the frequency and severity of adverse events,
May 08, 2019 04:01 pm ET
Aimmune Therapeutics Announces First Quarter 2019 Financial Results and Provides Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced financial results for the quarter ended March 31, 2019. For
the quarter ended March 31, 2019, net loss was $54.3 million and cash,
cash equivalents, and investments totaled $296.3 million on March 31,
2019.
May 01, 2019 08:00 am ET
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that it will host a conference call on Wednesday, May 8, 2019,
at 4:30 p.m. ET to discuss its financial results for the quarter ended
March 31, 2019, and recent operational highlights.
Apr 03, 2019 08:00 am ET
Aimmune Therapeutics to Present at 18th Annual Needham & Company Healthcare Conference
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that Jayson Dallas, M.D., President and Chief Executive
Officer, will present at the Needham & Company 18th
Annual Healthcare Conference on Wednesday, April 10, 2019, at 8:00 a.m.
Eastern Time in New York City.
Mar 25, 2019 08:00 am ET
European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that its phase 3 European clinical trial of AR101 for the
treatment of peanut allergy, known as ARTEMIS (AR101 Trial
in Europe Measuring oral Immunotherapy Success),
met its primary efficacy endpoint. Topline data show that the proportion
of AR101-treated patients who tolerated a 1,000-mg dose of peanut
protein (2,043 mg cumulative) in a blinded exit challenge
Mar 18, 2019 08:00 am ET
U.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that the Biologics License Application (BLA) for AR101 has
been accepted for review by the U.S. Food and Drug Administration (FDA).
Mar 05, 2019 08:15 am ET
Detailed Research: Economic Perspectives on Canopy Growth, Aimmune Therapeutics, Nektar Therapeutics, Workday, Workiva, and MAG Silver — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Canopy Growth Corporation (NYSE:CGC), Aimmune Therapeutics, Inc. (NASDAQ:AIMT),...
Mar 05, 2019 08:00 am ET
Aimmune Therapeutics to Participate in Three Investor Conferences in March
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that members of the Aimmune executive management team will
participate in three upcoming investor conferences in March:
Feb 28, 2019 04:01 pm ET
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced financial results for the fourth quarter and full year 2018.
Feb 25, 2019 08:00 am ET
Aimmune Therapeutics Presents New AR101 Data at AAAAI, Including Demonstrated Reduction in Accidental Exposures to Peanut Requiring Treatment
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today presented new data on AR101, its investigational treatment for
peanut allergy, at the American Academy of Asthma, Allergy and
Immunology (AAAAI) Annual Meeting in San Francisco, where the company
presented nine abstracts overall.
Feb 21, 2019 08:00 am ET
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that it will host a conference call on Thursday, February 28,
2019, at 5:00 p.m. ET to discuss its financial results for the quarter
and full-year ended December 31, 2018, and recent operational highlights.
Feb 04, 2019 10:33 am ET
Aimmune Therapeutics to Present AR101, OIT and Peanut Allergy Data at 2019 AAAAI Annual Meeting
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that it will present data on AR101, oral immunotherapy,
and peanut allergy at the 2019 American Academy of Asthma, Allergy and
Immunology (AAAAI) Annual Meeting, taking place February 22–25 in San
Francisco. All abstracts for the 2019 AAAAI Annual Meeting, which
focuses on “Food Allergy: Advances in Prevention and Treatment,” are
available at
Jan 18, 2019 08:00 am ET
Aimmune Therapeutics Appoints Andrew Oxtoby as Chief Commercial Officer
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced the appointment of Andrew Oxtoby as Chief Commercial
Officer. Mr. Oxtoby, a proven pharmaceutical executive with two decades
of experience in the healthcare and consumer products industries, will
join Aimmune in the newly created role on Tuesday, January 22.
Jan 04, 2019 08:45 am ET
Aimmune Therapeutics and KKR Enter into $170M Loan Agreement to Fund AR101 Commercialization and Pipeline Advancement
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that it has entered into a $170 million loan agreement
with an affiliate of KKR, a leading global investment firm.
Jan 03, 2019 07:35 am ET
Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of L3 Technologies Inc. (NYSE:LLL), The Goldman Sachs Group, Inc....
Jan 02, 2019 08:00 am ET
Aimmune Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7th
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that CEO Jayson Dallas, M.D., will present a company overview
at the 37th Annual J.P. Morgan Healthcare Conference in San
Francisco on Monday, January 7, 2019, at 3:00 p.m. Pacific Time. Dr.
Dallas will highlight recent progress, including the submission of a
Biologics License Application to the U.S. Food and Drug Administration
for AR101 in peanut allergy (ages 4-17), and provide an outlook
Dec 21, 2018 04:01 pm ET
Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 4–17
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that it has submitted a Biologics License Application
(BLA) to the U.S. Food and Drug Administration (FDA) for AR101, an
investigational biologic oral immunotherapy for the treatment of peanut
allergy in children and adolescents ages 4–17. The FDA granted AR101
Fast Track Designation for peanut allergy in September 2014 and
Breakthrough Therapy Designation for peanut allergy in ages 4–17 in
Dec 20, 2018 01:43 am ET
Aimmune Therapeutics Announces IND Filing for AR201 for Egg Allergy and Exclusive Supply Agreement with Michael Foods
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the submission of its investigational new drug (IND) application for AR201 for the treatment of egg allergy. The company also announced an exclusive supply agreement for egg protein with Michael Foods, Inc., the largest U.S. processor of value-added eggs. Aimmune expects to initiate a Phase 2 clinical trial of AR201 for the treatment of egg allergy in 2019.
Dec 19, 2018 08:00 am ET
Aimmune Therapeutics Initiates Phase 3 POSEIDON Trial for Treatment of Peanut Allergy in 1–3-Year-Old Children
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that it has initiated POSEIDON (Peanut Oral
Immunotherapy Study of Early Intervention for Desensitization),
an international, Phase 3 clinical trial of AR101 in peanut-allergic
children ages 1–3 years. AR101 is Aimmune’s investigational biologic
oral immunotherapy for desensitization of patients with peanut allergy.
Dec 06, 2018 08:00 am ET
Aimmune Therapeutics to Host Investor Symposium on the Future of Treating Peanut Allergy with Leading Expert Allergists on Wednesday, December 12th
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that it will host an Investor Symposium in New York City on
December 12, 2018. Aimmune’s senior management will discuss AR101’s
clinical profile in peanut-allergic patients and the company’s
preparations for a potential 2019 U.S. commercial launch. The event will
also bring together leading expert allergists to discuss the emerging
treatment landscape in peanut allergy, including the recent New
Nov 28, 2018 04:05 pm ET
Aimmune Therapeutics Announces Closing of $98 Million Investment by Nestlé Health Science
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced the closing of the $98 million equity investment by
Nestlé Health Science. Nestlé Health Science purchased 3,237,529 newly
issued shares of Aimmune’s common stock at $30.27 per share on November
28, 2018, in a private placement transaction. The sale of shares was
made pursuant to the terms of the Securities Purchase Agreement entered
into on November 11, 2018, by Aimmune and Nestlé Health Sc
Nov 28, 2018 07:20 am ET
Market Trends Toward New Normal in Genomic Health, Beacon Roofing Supply, Cronos Group, Aimmune Therapeutics, OGE Energy, and Spartan Motors — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Genomic Health, Inc. (NASDAQ:GHDX), Beacon Roofing Supply, Inc....
Nov 18, 2018 04:45 pm ET
Landmark PALISADE Trial of AR101 Published in New England Journal of Medicine
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that the New England Journal of Medicine (NEJM)
has published the full results of the landmark phase 3 PALISADE clinical
trial of AR101, Aimmune’s investigational biologic oral immunotherapy
for desensitization of patients with peanut allergy. PALISADE is the
largest and first successful phase 3 peanut allergy immunotherapy trial
to date.
Nov 12, 2018 08:00 am ET
Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that Nestlé Health Science will make an additional
equity investment in Aimmune of $98 million, increasing Nestlé Health
Science’s ownership of Aimmune to approximately 19 percent.
Nov 08, 2018 04:01 pm ET
Aimmune Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Highlights
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced financial results for the quarter and nine months ended
September 30, 2018. As of September 30, 2018, cash, cash equivalents and
investments totaled $255.2 million.
Nov 08, 2018 08:00 am ET
Aimmune Therapeutics Announces Presentations at 2018 ACAAI Annual Scientific Meeting
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that it will present data on AR101, oral immunotherapy
and peanut allergy at the American College of Asthma, Allergy and
Immunology (ACAAI) Annual Scientific Meeting, taking place November
15-19, 2018, in Seattle. AR101 is Aimmune’s investigational biologic
oral immunotherapy for desensitization of patients with peanut allergy.
Nov 02, 2018 08:00 am ET
Aimmune Therapeutics Announces Appointment of Dr. Brett Haumann to Board of Directors
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that Brett Haumann, M.B.B.Ch., M.B.A., has joined the
Aimmune Board of Directors, effective October 31, 2018. Dr. Haumann’s
extensive biotech and pharmaceutical leadership experience includes more
than 20 years of development and discovery work in allergy and pulmonary
medicines.
Nov 01, 2018 08:00 am ET
Aimmune Therapeutics to Participate in Upcoming Investor Conferences
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that members of senior management will participate in the
following investor conferences:
Oct 17, 2018 08:55 am ET
New Research: Key Drivers of Growth for IDT, Live Nation Entertainment, BioDelivery Sciences International, Spero Therapeutics, Aimmune Therapeutics, and Cars — Factors of Influence, Major Initiatives
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of IDT Corporation (NYSE:IDT), Live Nation Entertainment, Inc. (NYSE:LYV),...
Oct 15, 2018 08:00 am ET
Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced the initiation of a phase
2 study, with Regeneron and Sanofi, of AR101 with adjunctive
dupilumab in peanut-allergic patients. AR101 is Aimmune’s
inves
Sep 26, 2018 08:00 am ET
Aimmune Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 3
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that President and CEO Jayson Dallas, M.D., will participate
in a fireside chat at the Cantor Global Healthcare Conference in New
York on Wednesday, October 3, 2018, at 10:55 a.m. Eastern Time.
Aug 29, 2018 08:00 am ET
Aimmune Therapeutics to Present at Three Investor Conferences in September
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that members of senior management will present at three
investor conferences in September:
Aug 23, 2018 08:00 am ET
Report: Developing Opportunities within Aimmune Therapeutics, Everbridge, Roku, Bristow Group, Atlas Air Worldwide, and Edgewell Personal Care — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aimmune Therapeutics, Inc. (NASDAQ:AIMT), Everbridge, Inc. (NASDAQ:EVBG),...
Aug 08, 2018 04:01 pm ET
Aimmune Therapeutics Announces Second Quarter 2018 Financial Results
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced financial results for the quarter and six months ended June
30, 2018. As of June 30, 2018, cash, cash equivalents and investments
totaled $295.9 million.
Aug 07, 2018 08:00 am ET
Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that Jayson Dallas, M.D., will give his first public
presentation as the company’s President and CEO at the 2018 Wedbush
PacGrow Healthcare Conference in New York on Wednesday, August 15 at
1:55 p.m. Eastern Time.
Jun 15, 2018 07:40 am ET
New Research Coverage Highlights Avery Dennison, Raymond James Financial, Genuine Parts, Kimco Realty, Bristow Group, and Aimmune Therapeutics — Consolidated Revenues, Company Growth, and Expectations
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Avery Dennison Corporation (NYSE:AVY), Raymond James Financial, Inc....
Jun 11, 2018 04:01 pm ET
Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced the appointment of Jayson Dallas, M.D., as President and
Chief Executive Officer. Dr. Dallas, a biotech and pharmaceutical
industry executive with decades of global strategic and commercial
experience, will join Aimmune as President and CEO on June 19th, and
will also become a member of the Aimmune Board of Directors.
May 30, 2018 06:00 am ET
Aimmune Therapeutics Announces New Pan-European Study Showing Significant Psychosocial Burden Associated With Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that data from a new study on the psychosocial burden of
peanut allergy in European countries were presented at the European
Academy of Allergy and Clinical Immunology (EAACI) Congress 2018 in
Munich.
May 29, 2018 07:30 am ET
Aimmune Therapeutics Announces Data on Terminology Used with Oral Immunotherapy Were Presented at EAACI 2018
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that data on terminology used with oral immunotherapy
were presented at the European Academy of Allergy and Clinical
Immunology (EAACI) Congress 2018 in Munich.
May 28, 2018 11:15 am ET
Aimmune Therapeutics Announces New Clinical Data on AR101 for Peanut Allergy at the 2018 EAACI Congress
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
reported additional results from its pivotal Phase 3 PALISADE trial of
AR101 for the treatment of peanut allergy at the Congress of the
European Academy of Allergy, Asthma, and Immunology (EAACI) 2018 in
Munich. Aimmune previously announced that the trial met its primary and
secondary efficacy endpoints in the pre-specified primary analysis of
the 4-17 age cohort (
May 15, 2018 08:00 am ET
Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that it will present data on peanut allergy at the
European Academy of Allergy and Clinical Immunology (EAACI) Congress
2018, taking place May 26–30 in Munich.
May 09, 2018 08:00 am ET
Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that members of the Aimmune executive management team will
participate in four upcoming investor conferences in May and June:
May 08, 2018 04:01 pm ET
Aimmune Therapeutics Announces First Quarter 2018 Financial Results
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced financial results for the first quarter 2018. As of March 31,
2018, cash, cash equivalents and investments totaled $331.7 million.
Apr 19, 2018 08:15 am ET
Market Trends Toward New Normal in Genuine Parts, Energizer, Arthur J. Gallagher, Aimmune Therapeutics, Roku, and Premier — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Genuine Parts Company (NYSE:GPC), Energizer Holdings,...
Mar 12, 2018 08:00 am ET
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced financial results for the fourth quarter and full year 2017.
Mar 07, 2018 08:00 am ET
Aimmune Therapeutics to Participate in Four Investor Conferences in March
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that members of the Aimmune executive management team will
participate in four upcoming investor conferences in March:
Mar 04, 2018 02:00 pm ET
Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
announced that the results of its pivotal Phase 3 PALISADE trial of
AR101 for the treatment of peanut allergy were presented today at the
2018 American Academy of Allergy, Asthma & Immunology–World Allergy
Organization Joint Congress in Orlando. Aimmune previously
Mar 02, 2018 04:01 pm ET
Aimmune Therapeutics Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that the underwriters of its previously announced
underwritten public offering of 5,500,000 shares of its common stock at
a price to the public of $32.00 per share have exercised in full their
option to purchase an additional 825,000 shares of common stock at the
public offering price, less underwriting discounts and commissions.
After giving effect to the closing on February 26, 2018, and t
Feb 27, 2018 07:00 am ET
Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results on Sunday, March 4, at the AAAAI-WAO Joint Congress in Orlando
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that it will host an Analyst and Investor Event on the evening
of March 4, 2018, at the joint congress of the American Academy of
Asthma, Allergy and Immunology (AAAAI) and the World Allergy
Organization (WAO) in Orlando, Florida, following a late-breaking oral
presentation of the company's Phase 3 PALISADE trial results earlier
that afternoon.
Feb 26, 2018 04:01 pm ET
Aimmune Therapeutics Announces Closing of Public Offering of Common Stock
Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced the completion of its previously announced underwritten
public offering of 5,500,000 shares of its common stock at a price to
the public of $32.00 per share. All shares in the offering were sold by
Aimmune, with gross proceeds to Aimmune of $176.0 million and net
proceeds of approximately $164.2 million, after deducting underwriting
discounts and commissions and estimated offering expenses.
Feb 21, 2018 07:28 pm ET
Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock
Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced the pricing of an underwritten public offering of
5,500,000 shares of its common stock at a price to the public of $32.00
per share, for gross proceeds of $176 million before deducting estimated
underwriting discounts and commissions and estimated offering expenses
payable by Aimmune. All of the shares to be sold in the offering will be
offered by Aimmune. In addition, Aimmune has granted th
Feb 20, 2018 04:16 pm ET
Aimmune Therapeutics Announces Proposed Public Offering of Common Stock
Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that it has commenced an underwritten public offering of
up to $150,000,000 of shares of its common stock. All of the shares to
be sold in the offering will be offered by Aimmune. In addition, Aimmune
expects to grant the underwriters of the offering a 30-day option to
purchase up to an additional $22,500,000 of shares of common stock at
the public offering price, less underwriting discounts
Feb 20, 2018 07:00 am ET
Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that its pivotal Phase 3 PALISADE efficacy trial of
AR101 met the primary endpoint. In the United States, AR101 has U.S.
Food and Drug Administration (FDA) Breakthrough Therapy Designation for
peanut-allergic patients ages 4–17.
Feb 14, 2018 08:00 am ET
Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D.
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced the expansion of its Scientific Advisory Board with the
appointments of George du Toit, M.B., B.Ch., a Professor of Paediatric
Allergy at King’s College London, Guy’s and St. Thomas’ NHS Foundation
Trust, and Wayne G. Shreffler, M.D., Ph.D., Chief of Pediatric Allergy
and Immunology and Director of the Food Allergy Center at Massachusetts
General Hospital and Associate Professor of Pediatric
Feb 12, 2018 08:15 am ET
Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that it will present data during a late-breaking oral
abstract session and in poster sessions at the 2018 American Academy of
Allergy, Asthma & Immunology–World Allergy Organization Joint Congress,
taking place March 2–5 in Orlando. The Congress abstracts were posted
online today at
Feb 08, 2018 08:15 am ET
Report: Exploring Fundamental Drivers Behind Stericycle, Hemisphere Media Group, Expedia, Olin, Aimmune Therapeutics, and Waste Management — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Feb. 08, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Stericycle, Inc. (NASDAQ:SRCL), Hemisphere Media Group,...
Jan 10, 2018 08:00 am ET
Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced an expansion and extension of its exclusive supply
agreement with Golden Peanut and Tree Nuts (Golden), a subsidiary of
Archer Daniels Midland Company (ADM), to support the anticipated
potential commercialization of AR101. Golden is a leading handler,
processor and exporter of peanuts and tree nuts and exclusively supplies
the starting material for AR101, Aimmune’s investigational biologic o
Jan 08, 2018 08:00 am ET
Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced its outlook for the coming year, including its plans to
report topline results in February from its pivotal Phase 3 PALISADE
trial of AR101 for peanut allergy, following the completion of the
554-subject trial in late 2017. AR101 is Aimmune’s investigational
biologic oral immunotherapy (OIT) for desensitization of patients with
peanut allergy.
Jan 03, 2018 08:00 am ET
Aimmune Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a
company overview at the 36th Annual J.P. Morgan Healthcare Conference in
San Francisco on Wednesday, January 10, 2018, at 7:30 a.m. Pacific Time.
A breakout session will immediately follow the presentation.
Dec 07, 2017 08:00 am ET
Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that Chief Financial Officer Eric Bjerkholt will participate
in a fireside chat at the BMO Capital Markets 2017 Prescriptions for
Success Healthcare Conference on Thursday, December 14, 2017, in New
York City.
Nov 20, 2017 08:00 am ET
Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that it will host an Investor Symposium in New York City on
December 1, 2017. The event will bring together leading expert
allergists to discuss the emerging treatment landscape in peanut allergy.
Nov 20, 2017 07:35 am ET
Report: Developing Opportunities within UGI, Party City Holdco, Old Dominion Freight Line, Olin, Aimmune Therapeutics, and Waste Management — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- In new a independent research report released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of UGI Corporation (NYSE:UGI), Party City...
Nov 06, 2017 08:30 am ET
Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced financial results for the quarter and nine months ended
September 30, 2017. As of September 30, 2017, cash, cash equivalents,
and investments totaled $212.0 million.
Nov 01, 2017 08:00 am ET
Aimmune Therapeutics to Participate in Four Investor Conferences in November
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that members of the Aimmune executive management team will
participate in four upcoming investor conferences in November.
Oct 31, 2017 08:30 am ET
Aimmune Therapeutics Announces Publication in The Journal of Allergy and Clinical Immunology: In Practice of Positive AR101 Data from ARC001 Phase 2 Clinical Trial
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced the online publication of positive data from its ARC001
Phase 2 clinical trial of AR101 in The
Oct 19, 2017 08:00 am ET
Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced that it will present data on peanut allergy during
poster sessions at two upcoming medical meetings.
Oct 16, 2017 07:30 am ET
Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy
Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced a clinical collaboration with Regeneron and its
strategic alliance collaborator Sanofi to study AR101 treatment with
adjunctive dupilumab in peanut-allergic patients in a Phase 2 clinical
trial. Regeneron will sponsor the trial, with Aimmune to provide
clinical supply of AR101 and food challenge materials.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.